1. Antitumoral effect of PLK-1-inhibitor BI2536 in combination with cisplatin and docetaxel in squamous cell carcinoma cell lines of the head and neck
   JENS WAGENBLAST et al, 2013, Molecular and Clinical Oncology CrossRef
2. Inhibition of Polo-Like Kinase 1 Induces Cell Cycle Arrest and Sensitizes Glioblastoma Cells to Ionizing Radiation
   Julia Alejandra Pezuk et al, 2013, Cancer Biotherapy and Radiopharmaceuticals CrossRef
3. Molecular Targeting of the Oncoprotein PLK1 in Pediatric Acute Myeloid Leukemia: RO3280, a Novel PLK1 Inhibitor, Induces Apoptosis in Leukemia Cells
   Na-Na Wang et al, 2015, International Journal of Molecular Sciences CrossRef
4. Targeting the Mitotic Catastrophe Signaling Pathway in Cancer
   Margaret M. Mc Gee, 2015, Mediators of Inflammation CrossRef
5. Targeting of c-MET and AXL by cabozantinib is a potential therapeutic strategy for patients with head and neck cell carcinoma
   Anais Hagege et al, 2022, Cell Reports Medicine CrossRef
6. Mitosis-targeting therapies: a troubleshooting guide
   Elena Doménech et al, 2013, Current Opinion in Pharmacology CrossRef
7. Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors
   Ming Zhang et al, 2017, Cancer Letters CrossRef
8. Targeted Treatment of Head and Neck (Pre)Cancer: Preclinical Target Identification and Development of Novel Therapeutic Applications
   Anne M. van Harten et al, 2021, Cancers CrossRef
9. Theoretical studies on benzimidazole and imidazo[1,2-a]pyridine derivatives as Polo-like kinase 1 (Plk1) inhibitors: Pharmacophore modeling, atom-based 3D-QSAR and molecular docking approach
   Rajasekhar Chekkara et al, 2017, Journal of Saudi Chemical Society CrossRef
10. Evaluation of Polo‐like kinase 1 as a potential therapeutic target in Merkel cell carcinoma
    Lorenz Kadletz et al, 2016, Head & Neck CrossRef